[1] |
Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013:a systematic analysis for the Global Burden of Disease Study[J]. Lancet, 2014, 384(9945):766-781.
|
[2] |
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis[J]. Am J Med, 2009, 122(3):248-256.
|
[3] |
Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes:a systematic review[J]. JAMA, 2013, 309(21):2250-2261.
|
[4] |
Dixon JB, O'Brien PE, Playfair J,et al.Adjustable gastric banding and conventional therapy for type 2 diabetes:a randomized controlled trial[J]. JAMA, 2008, 299(3):316-323.
|
[5] |
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med,2012, 366(17):1577-1585.
|
[6] |
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes[J]. N Engl J Med, 2012, 366(17):1567-1576.
|
[7] |
Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes,hypertension, and hyperlipidemia:the Diabetes Surgery Study randomized clinical trial[J]. JAMA, 2013, 309(21):2240-2249.
|
[8] |
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications[J]. JAMA, 2014,311(22):2297-2304.
|
[9] |
Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013[J]. Endocr Pract, 2013,19(2):327-336.
|
[10] |
Dixon JB, Zimmet P, Alberti KG, et al. Bariatric surgery:an IDF statement for obese Type 2 diabetes[J]. Diabet Med, 2011, 28(6):628-642.
|
[11] |
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy:a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes[J]. Diabetologia, 2009, 52(1):17-30.
|
[12] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013版) [J].中国糖尿病杂志, 2014, 22(8):2-42.
|
[13] |
Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes:a community-based cohort study[J]. Am J Gastroenterol, 2010,105(7):1567-1573.
|
[14] |
Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus[J]. Gastroenterol Hepatol, 2004,19(8):854-858.
|
[15] |
Bhala N, Jouness RI, Bugianesi E, et al. Epidemiology and natural history of patients with NAFLD[J]. Curr Pharm Des, 2013,19(29):5169-5176.
|
[16] |
Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosiss in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2009, 7(11):1224-1229.
|